01—Abstract
Summary
Summary of the 10-K filed February 6, 2025. Cited figures are marked; the original filing is the authoritative source.
Philip Morris International Inc. (PM) reported robust growth in its smoke-free product portfolio, driven by the strong performance of IQOS and ZYN brands, which continues to be a key driver of the company's transformation.
Net revenues increased by 7.7% to $37.9 billiona, with smoke-free products contributing significantly to this growth. Despite a notable impairment charge of $2.3 billion related to its investment in Rothmans, Benson & Hedges Inc. (RBH), the company demonstrated resilience, with operating income increasing by 16.0% year-over-year.
PMI's strategic focus on a smoke-free future is evident in its continued investment in R&D and commercialization of these products. The company is navigating a complex regulatory and economic landscape, including inflationary pressures and geopolitical events, but maintains a strong financial position with significant cash flows from operations and ample liquidity.
02—Key points
Key Highlights
- Net revenues increased by 7.7% to $37.9 billion, driven by strong performance in smoke-free products and favorable pricing.
- Operating income rose by 16.0% year-over-year, demonstrating the company's ability to manage costs and leverage growth.
- A significant impairment charge of $2.3 billion related to the RBH equity investment impacted diluted EPS, resulting in a decrease from $5.02 in 2023 to $4.52 in 2024.
- Shipment volume for heated tobacco units (HTUs) increased by 11.6%, and oral SFP volume (primarily ZYN nicotine pouches) grew by 27.8%, highlighting the success of PMI's smoke-free transition.
- The company is progressing with its smoke-free product manufacturing capacity expansion, including investments in ZYN capacity in the U.S.
- PMI continues to actively manage its debt, reducing total debt by $2.2 billion to $45.7 billion and maintaining strong liquidity with $4.2 billion in cash and cash equivalents.
- The company's commitment to returning capital to shareholders is demonstrated by $8.2 billion in dividends paid in 2024, including a 3.8% increase in the quarterly dividend.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2024, Philip Morris International Inc. kept $0.19.
- Revenue$37.88B100.0%
- Cost of revenue−$13.33B35.2%
- Gross profit$24.55B64.8%
- Operating costs−$11.15B29.4%
- Operating income$13.40B35.4%
- Interest, other & tax−$6.34B16.8%
- Net income$7.06B18.6%
Where FY2024 revenue went
$37.88B- Cost of revenue: $13.33B, 35% of revenue
- Other operating costs: $10.39B, 27% of revenue
- Net income: $7.06B, 19% of revenue
- Interest, other & tax: $6.34B, 17% of revenue
- R&D: $759.0M, 2.0% of revenue
Kept 19% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 6, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $37.88B$35.17B | +7.7% |
| Cost of Revenue | $13.33B$12.89B | +3.4% |
| Gross Profit | $24.55B$22.28B | +10.2% |
| R&D Expenses | $759.00M$709.00M | +7.1% |
| Operating Income | $13.40B$11.56B | +16.0% |
| Net Income | $7.06B$7.81B | −9.7% |
| EPS (Basic) | $4.53$5.02 | −9.8% |
| EPS (Diluted) | $4.52$5.02 | −10.0% |
| Shares Outstanding (Basic) | 1.55B1.55B | +0.1% |
| Shares Outstanding (Diluted) | 1.56B1.55B | +0.2% |
05—Questions
Frequently Asked Questions
What was the primary driver of Philip Morris International's revenue growth in 2024?
Philip Morris International's revenue growth was primarily driven by its smoke-free products, with significant contributions from the IQOS and ZYN brands. Favorable pricing, particularly in combustible tobacco, and an increase in smoke-free product volumes also played a key role.
What is the impact of the RBH impairment charge on the company's financial performance?
The impairment charge of $2.3 billion related to Philip Morris International's investment in Rothmans, Benson & Hedges Inc. (RBH) significantly impacted the company's diluted earnings per share for 2024, reducing it by $1.49. While this is a substantial non-cash charge, the underlying business operations showed strong growth.
How is PMI advancing its 'smoke-free future' strategy?
PMI is advancing its 'smoke-free future' strategy through substantial investment in the development, scientific substantiation, and commercialization of smoke-free products, such as IQOS (heated tobacco) and ZYN (oral nicotine pouches). The company is expanding its manufacturing capacity for these products and actively promoting consumer switching from cigarettes.
What is the company's outlook for smoke-free products in 2025?
For the full year 2025, PMI expects smoke-free product shipment volume growth of 12% to 14%, with a specific expectation for U.S. nicotine pouch shipment volume to reach 780 to 820 million cans. This indicates continued strong momentum in the transition to smoke-free alternatives.
06—Continue